Fenoldopam: A new dopamine agonist for the treatment of hypertensive urgencies and emergencies

Journal of Clinical Pharmacology

Volumn 38, Issue 1, 1998, Pages 2-13

  Post IV, James B ^a   Frishman, William H ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 1 RECEPTOR STIMULATING AGENT; FENOLDOPAM; NITROPRUSSIDE SODIUM;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; DIURESIS; DRUG INDICATION; DRUG MECHANISM; EMERGENCY TREATMENT; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; NATRIURESIS; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PHARMACODYNAMICS; TACHYCARDIA; VASODILATATION;

EID: 0031885604     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04369.x     Document Type: Article

References (65)

1. Abdelwahab W, Frishman W, Landau A: Management of hypertensive urgencies and emergencies. J Clin Pharmacol 1995;35:747-762.
2. Hackman BB, Griffin B, Mills M, Ramanathan KB: Comparative effect of fenoldopam mesylate and nitroprusside on left ventricular performance in severe systemic hypertension. Am J Cardiol 1992;69:918-922.
3. Yoshimura M, Ikegaki I, Nishimura M, Takahashi H: Role of dopaminergic mechanisms in the kidney for the pathogenesis of hypertension. Auton Pharmacol 1990:10(Suppl 1):S67-S72.
4. Kinoshita S, Sidhu A, Felder RA: Defective dopamine-1 receptor adenylate cyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rat. J Clin Invest 1989;84:1849-1856.
5. Goldberg LI, Kohli JD: Peripheral pre- and post-synaptic dopamine receptors: are they different from the receptors in the central nervous system? Commun Psychopharmacol 1979;3:447-456.
6. Lee MR: Dopamine and the kidney: 10 years on. Clin Sci 1993;84:357-375.
7. Goldberg LI, Murphy MB: Dopamine. In, Messerli FH (ed.): Cardiovascular Drug Therapy. Philadelphia: WB Saunders, 1990;1083-1089.
8. Lokhandwala MF, Hedge SS: Cardiovascular pharmacology of adrenergic and dopaminergic receptors: therapeutic significance in congestive heart failure. Am J Med 1991;90(Suppl 5B):2S-9S.
9. Carey RM, Thorner MO, Ortt EM: Dopaminergic inhibition of metoclopramide induced aldosterone secretion in man: dissociation of responses to dopamine and bromocriptine. J Clin Invest 1980;66:10-18.
10. Carey RM: Dopamine, hypertension, and the potential for agonist therapy. In, Laragh JH, Renner BM (eds.): Hypertension: Pathophysiology, Diagnosis, and Management. Second edition. New York: Raven Press, 1995;2937-2952.
11. Francis GS, Wilson BC, Rector TS: Hemodynamic, renal, and neurohumoral effects of a selective oral DA1 selective agonist (fenoldopam) in patients with congestive heart failure. Am Heart J 1988;116:473-479.
12. Holcslaw TL, Beck TR: Clinical experience with intravenous fenoldopam. Am J Hypertens 1990;3:120S-125S.
13. Berkowitz BA, Erikson R, Zabko-Potapovich B, et al: Vascular dopamine and dopamine receptor agonists. In, Poste G, Crooke ST (eds.): Dopamine Receptor Agonists. New York: Plenum Press, 1984;195-208.
14. Ackerman DM, Weinstock J, Weibelhaus VD, Berkowitz B: Renal vasodilators and hypertension. Drug Devel Res 1982;2:283-297.
15. Ackerman DM, Blumberg AL, McCafferty JP, Sherma SS, Weinstock J, Kaiser C, Berkowitz B: Potential usefulness of renal vasodilators in hypertension and renal disease: SK&F 82526. Fed Proc 1983;42:186-190.
16. Stote RM, Dubb JW, Familiar RG, Erb BB, Alexander F: A new oral renal vasodilator, fenoldopam. Clin Pharmacol Ther 1983;34:309-315.
17. Ohlstein EH, Zabko-Potapovich B, Berkowitz BA: Studies on dopamine vascular receptors with the dopamine receptor agonist: SK&F 82526. J Pharmacol Exp Ther 1984;229:433-439.
18. Hughes A, Thom S, Martin G, Redman D, Hasan S, Server P: The action of a dopamine (DA1) receptor agonist, fenoldopam, in human vasculature in vivo and in vitro. Br J Clin Pharmacol 1986;22:535-540.
19. Nichols AJ, Ruffolo RR Jr., Brooks DP: The pharmacology of fenoldopam. Am J Hypertens 1990;3:116S-119S.
20. Ohlstein EH, Zabko-Potapovich B, Berkowitz BA: The DA1 receptor agonist fenoldopam (SK&F 82526) is also an alpha 2-adrenoceptor antagonist. Eur J Pharmacol 1985;118:321-328.
21. Nakamura S, Kohli JD, Rajfer SI: Alpha-adrenoceptor blocking activity of fenoldopam (SK&F 82526), a selective DA1 agonist. J Pharm Pharmacol 1986;38:113-117.
22. Kohli JD, Glock D, Goldberg LI: Relative DA1-dopamine receptor agonist and alpha-adrenoceptor antagonist activity of fenoldopam in the anesthetized dog. J Cardiovasc Pharmacol 1988;11:123-126.
23. Szabo B, Hedler L, Starke K: Dopamine 1 receptor agonist and alpha-2 adrenoceptor antagonist effects of fenoldopam in rabbits. J Pharmacol Exp Ther 1986;239:881-886.
24. Murphy MB, Weber RR, Nelson K, Goldberg LI: The role of alpha-adrenoceptor blockade in the antihypertensive effects of fenoldopam in humans. Clin Pharmacol Ther 1988;44:49-55.
25. Alison NL, Dubb JW, Ziemniak JA, Alexander F, Stote RM: The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther 1987;41:282-288.
26. Carey RM, Stote RM, Dubb JW, Townsend LH, Rose CE Jr., Kaiser DL: Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. J Clin Invest 1984;74:2198-2207.
27. Gluck Z, Jossen L, Weidmann P, Gnadinger MP, Peheim E: Cardiovascular and renal profile of acute peripheral dopamine-1 receptor agonism with fenoldopam. Hypertension 1987;10:43-54.
28. Ventura HO, Messerli FH, Frohlich ED, Kobrin I, Oigman W, Dunn FG, Carey RM: Immediate hemodynamic effects of a dopamine receptor agonist (fenoldopam) in patients with essential hypertension. Circulation 1984;69:1142-1145.
29. Caruana MP, Herber M, Brigden G, Raftery EB: Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hvpertension. Br J Clin Pharmacol 1987;24:721-727.
30. Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL: Randomized, prospective trial of fenoldopam versus sodium nitroprusside in the treatment of acute severe hypertension. Acad Emerg Med 1995;2:959-965.
31. Bednarczyk EM, White WB, Munger MA, Gonzalez FM, Panacek EA, Weed SG, et al: Comparative acute blood pressure reduction from intravenous fenoldopam mesylate versus sodium nitroprusside in severe systemic hypertension. Am J Cardiol 1989;63:993-996.
32. White WB, Radford MJ, Gonzalez FM, Weed SG, McCabe EJ, Katz AM: Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. J Am Coll Cardiol 1988;11:1118-1121.
33. Elliott WJ, Weber RR, Nelson KS, Oliner CM, Fumo MT, Gretler DD, et al: Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation 1990;81:970-977.
34. Bodmann KF, Troster S, Clemens R, Schuster HP: Hemodynamic profile of intravenous fenoldopam in patients with hypertensive crisis. Clin Invest 1993;72:60-64.
35. Munger MA, Rutherford WF, Anderson L, Hakki AI, Gonzalez FM, Bednarczyk EM, et al: Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. Crit Care Med 1990;18:502-504.
36. Pilmer BL, Green JA, Panacek EA, Elliot WJ, Murphy MB, Rutherford W, Nara AR: Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension. J Clin Pharmacol 1993;33:549-553.
37. Young JB, Leon CA, Pratt CM, Saurez JM, Aronoff RD, Roberts R: Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure. J Am Coll Cardiol 1985;6:792-796.
38. Goldberg LI: The role of dopamine receptors in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1989;14:S19-S27.
39. Young JB, Leon CA, Pratt CM, Kingry C, Taylor AA, Roberts R: Intravenous fenoldopam in heart failure: comparing the hemodynamic effects of dopamine 1 receptor agonism with nitroprusside. Am Heart J 1988;115:378-384.
40. Carey RM, Hughes JM: Selective renal dopamine-1 receptor stimulation in man. Clin Exp Hypertens 1987;A9:1009-1020.
41. Girbes AR, Smit AJ, Meijer S, Reitsma WD: Renal and endocrine effects of fenoldopam and metoclopramide in normal man. Nephron 1990;56:179-185.
42. Hughes JM, Ragsdale NV, Felder RA, Chevalier RL, King B, Carey RM: Diuresis and natriuresis during continuous dopamine-1 receptor stimulation. Hypertension 1988;11(Part 2, Suppl):I69-I74.
43. Bunghi S, Horton R, Antonipillai I, Manoogian C, Ehrlich L, Nadler J: Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects. J Clin Endocrinol Metab 1989;69:1116-1121.
44. Murphy MB, McCoy CE, Weber RR, Fredrickson ED, Douglas FL, Goldberg LI: Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of dopamine 1 agonist fenoldopam. Circulation 1987;76:1312-1318.
45. Shusterman NH, Elliott WJ, White WB: Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 1993;95:161-168.
46. White WB, Halley SE: Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med 1989;149:870-874.
47. Boesgaard S, Hagen C, Anderson AN, Eldrup E, Lange P: Effect of fenoldopam, a dopamine-1 receptor agonist, on pituitary, gonadal and thyroid hormone secretion. Clin Endocrinol 1989;30:231-239.
48. Hahn RA, Wardell JR Jr., Sarau HM, Ridley PT: Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine agonist. J Pharmacol Exp Ther 1982;223:305-313.
49. Harvey JN, Worth DP, Brown J, Lee MR: Studies with fenoldopam, a dopamine-1 agonist, in essential hypertension. Br J Clin Pharmacol 1986;21:53-61.
50. Blanchett DG, Green JA, Nara A, Pospisil R, Jarvis RC, Kasmer RJ, et al: The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. Clin Pharmacol Ther 1991;49:449-456.
51. Clancy A, Locke-Haydon J, Cregeen RJ, Ireson M, Ziemniak JA: Effects of concomitant food intake on absorption kinetics of fenoldopam (SK&F 82526) in healthy volunteers. Eur J Clin Pharmacol 1987;32:103-106.
52. Ziemniak JA, Boppana VK, Cyronak MJ, Beck TR, Familiar RG, Dubb JW, et al: Continuous intra-gastric delivery of fenoldopam: relationship between plasma concentration and effects on renal function. Br J Clin Pharmacol 1988;25:367-373.
53. Weber RR, McCoy CE, Ziemniak JA, Frederickson ED, Goldberg LI, Murphy MB: Pharmacokinetics and pharmacodynamic properties of intravenous fenoldopam. Br J Clin Pharmacol 1988;25:17-21.
54. Goldberg ME, Cantillo J, Nemiroff MS, Subramoni J, Munoz R, Torjman M, Schieren H: Fenoldopam infusion for the treatment of postoperative hypertension. J Clin Anesth 1993;5:386-391.
55. Hill AJ, Feneck RO, Walesby RK: Comparison of fenoldopam with nitroprusside in the control of hypertension following coronary artery surgery. J Cardiothorac Vasc Anesth 1993;7:279-284.
56. Kostowski W: Peripheral dopamine receptor agonists as potential drugs in diseases of the circulatory system. Pol Tyg Lek 1985;40:1448-1451.
57. Reisin E, Huth MM, Nguyen BP, Weed SG, Gonzalez FM: Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension 1990;15:159-62.
58. Karnesiz TA, Murphy MB, Weber RR, Nelson KS, Tripathi RC: Effects of selective dopamine-1 receptor activation on intraocular pressure in man. Exp Eye Res 1988;47:689-697.
59. Elliott WI, Karnezis TA, Silverman RA, Geanon J, Tripathi RC, Murphy MB: Intraocular pressure increases with fenoldopam, but not nitroprusside in hypertensive humans. Clin Pharmacol Ther 1991;49:285-293.
60. Ziemniak IA, Allison N, Boppana VK, Dubb J, Stote R: The effect of acetaminophen on the disposition of fenoldopam: competition for sulfation. Clin Pharmacol Ther 1987;41:275-281.
61. Strocchi E, Tartagni F, Malini PL, Valtancoli G, Ambrosioni E, Pasinelli F, et al: Interaction study of fenoldopam-digoxin in congestive heart failure. Eur J Clin Pharmacol 1989;37:395-397.
62. Clark KL, Hilditch A, Robertson MJ, Drew GM: Effect of dopamine-1 receptor blockade and angiotensin converting enzyme inhibition on the renal actions of fenoldopam in the anesthetized dog. J Hypertens 1991;9:1143-1150.
63. Brogden RN, Markham A: Fenoldopam. Drugs 1997;54:634-650.
64. Frishman WH, Hotchkiss H: Selective and nonselective dopamine receptor agonists: an innovative approach to cardiovascular disease treatment. Am Heart J 1996;132:861-870.
65. Frishman WH, Hotchkiss H: Selective and nonselective dopamine receptor agonists. In, Frishman WH, Sonnenblick EH (eds.): Cardiovascular Pharmacotherapeutics. New York: McGraw Hill, 1997;727-737.